MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1126/scitranslmed.adi4505

Медицинская библиотека · Science translational medicine · 2025

Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial.

Gomez-Mancilla Baltazar, Dürsteler Kenneth M, Vogel Marc, Herdener Marcus, Torrens Marta, Gálvez Bartolomé P, Gual Antoni, Corral Ricardo M, Kuper Enrique I, Mosca Daniel L, Dumitras Swati, Pezous Nicole, Berkheimer Maria, Walker Ela, Gasparini Fabrizio, Cha Jang-Ho, Dolmetsch Ricardo

СтатьяКлиническое исследование II фазыРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

Metabotropic glutamate receptor 5 (mGluR5) is involved in cocaine reward processing and addiction. Preclinical studies suggest that blocking this receptor inhibits cocaine self-administration and seeking behavior in rodents. We assessed a selective noncompetitive antagonist of mGluR5 called mavoglurant in a phase 2 randomized, placebo-controlled clinical trial of 68 adults with cocaine use disorder. Study participants were randomly assigned in a 1:1 ratio to an up-titrating schedule of oral mavoglurant twice daily up to 200 mg for 98 days or placebo. The primary end point was the proportion of cocaine use days over the treatment period assessed by a retrospective self-report using Timeline Followback. Secondary end points were urine analysis of the cocaine metabolite benzoylecgonine and alcohol use measured by Timeline Followback assessment. Exploratory end points included testing for cocaine and alcohol metabolites in hair samples. The posterior probability of mavoglurant reducing cocaine use at the end of treatment was ≥99.0% for a treatment difference <0 and ≥36.6% for a treatment difference <-10%. The difference between mavoglurant and placebo was also assessed using analysis of covariance (P = 0.021). Urine benzoylecgonine concentration was lower in the mavoglurant-treated group versus placebo (P = 0.025); there was reduced alcohol consumption in the treatment group (P = 0.072). Seventy-six percent (randomized set) and 79% (safety analysis set) of patients completed the final treatment visit. Adverse events in the treatment group were headache, dizziness, and nausea. In this small and short trial, mavoglurant reduced cocaine and alcohol use in patients with chronic cocaine use disorder.

Для цитирования: Gomez-Mancilla Baltazar, Dürsteler Kenneth M, Vogel Marc, Herdener Marcus, Torrens Marta, Gálvez Bartolomé P, Gual Antoni, Corral Ricardo M, Kuper Enrique I, Mosca Daniel L, Dumitras Swati, Pezous Nicole, Berkheimer Maria, Walker Ela, Gasparini Fabrizio, Cha Jang-Ho, Dolmetsch Ricardo. Mavoglurant reduces cocaine use in patients with cocaine use disorder in a phase 2 clinical trial.. Science translational medicine. 2025. DOI: 10.1126/scitranslmed.adi4505.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.